Sustainability & Social Responsibility

Psoriasis affects 2% of the global population, i.e., over 150 million people. There is clearly a large burden posed on the global population by this disease and through the development of our novel treatment, we can address this burden and subsequently contribute towards SDG 3: Good Health and Well-being.

Through our work in the development, manufacturing and distribution of our novel psoriasis treatment, we will contribute to the growth of the pharmaceutical industry and create more jobs for the local communities in the process. Our therapy will also work to reduce the suffering of psoriasis patients and improve their quality of life, subsequently reducing the number of sick-days from work lost each year to psoriasis-related symptoms and complications. Ultimately, this will contribute to furthering SDG 8: Decent Work and Economic Growth.

Taking into consideration the over-consumption of plastic negatively impacting the environment across the globe, we are committed to responsible consumption of plastic and other materials were possible. Because of its mechanism of action, our drug allows for less frequent dosaging when compared to other psoriasis treatments on the market. This means ultimately, we will use less plastic in our production and packaging, contributing towards SDG 12: Responsible Consumption.